Olympus Narrow Band Imaging (NBI) is an optical technology available for a variety of medical disciplines which helps to visualize the minutest vascular and mucosal patterns. NBI uses only wavelengths absorbed by hemoglobin for maximum contrast. A number of studies highlight the clinical value of NBI, especially with regard to the detection of cancer and characterization of suspicious mucosal areas. Compared to white-light endoscopy, the images of capillaries are less blurred and the probability of missing a lesion is reduced.
Practical Advantages of NBI
- One platform throughout a hospital.
- Increases quality of care by improving visibility, and facilitating optical diagnosis and the delineation of lesions.
- No preparation required — technology available at the touch of a button at no extra cost.
- Comprehensive training is available online and face-to-face with renowned experts.
Narrow Band Imaging Guides the Detection of Neoplastic Changes in Barrett’s Esophagus*
NBI proved to be a reliable modality for targeted biopsy in Barrett’s esophagus — identifying more neoplasia but requiring significantly fewer biopsies.1,2 Although biopsy cannot be avoided completely, NBI may improve the quality and cost-effectiveness of Barrett’s esophagus surveillance.
With the BING criteria, a comprehensive binary classification system to identify high-grade dysplasia and adenocarcinoma has been developed by renowned Barrett’s experts.3
In 2016, the American Society for Gastrointestinal Endoscopy (ASGE) endorsed the use of NBI for targeted biopsy in Barrett’s esophagus surveillance.4
*Image courtesy of Prof. Dr. Stefan Seewald, Gastrozentrum Hirslanden, Zürich
Barrett’s Surveillance with GIF-EZ1500 and NBI
Using an innovative two-stage optical system, HQ and EZ endoscopes allow you to switch between two focus settings, “normal mode” and “near mode,” which overlap so that there is no focus gap. Near focus in our EDOF endoscopes CF-EZ1500DL/I and GIF-EZ1500 provides up to 90-100×** magnification.
** Tested with Olympus OEV321UH monitor.
Narrow Band Imaging Increases the Detection of Squamous Cell Carcinoma
Esophageal and head and neck squamous cell carcinoma are often detected at a late stage due to the usually flat appearance and minimal color change in white light imaging. The delayed detection of SCC contributes to its poor five-year survival rate of less than 25%.5
NBI has been shown to significantly increase detection rates for SCC, thus contributing to earlier treatment and a potentially better prognosis.6 The visualization of distinct intrapapillary capillary loops (IPCL) patterns helps experts to predict infiltration depth, hence guiding therapy decisions.7
Narrow Band Imaging Enables High-Confidence Optical Diagnosis of Colorectal Lesions
NBI has been extensively studied with favorable outcomes for the assessment of colorectal lesions. It not only increases adenoma detection rates if bowel preparation is good.8 NBI also allows for highly accurate optical predictions of polyp histology with >90% negative predictive value (NPV) and >90% surveillance interval agreement with histopathology.9
As the most validated and broadly available virtual chromoendoscopy technology, European and American gastroenterology societies (ESGE, ASGE and NICE) have endorsed the use of NBI for the optical diagnosis of colorectal polyps.10,11,12
NBI Optical Diagnosis Training
Olympus is committed to providing the most advanced technologies for endoscopic diagnosis and treatment, helping you to advance patient care.Try out our NBI training portal
1 – Qumseya et al. Clin Gastroenterol Hepatol. 2013 Dec;11(12):1562-70.e1-2.
2 – Sharma et al. Gut. 2013 Jan;62(1):15-21.
3 – Sharma et al. Gastroenterology. 2016 Mar;150(3):591-8.
4 – Thosani et al. Gastrointest Endosc. 2016 Apr;83(4):684-98.e7.
5 – Muto, Manabu et al., “Early Detection of Superficial Squamous Cell Carcinoma in the Head and Neck Region and Esophagus by Narrow Band Imaging: A Multicenter Randomized Controlled Trial,” Journal of Clinical Oncology, 28 (9), 2010, p. 1570.
6 - Then et al. World J Oncol. 2020 Apr; 11(2): 55–64.
7 – Muto et al. J Clin Oncol. 28 (9), 2010, 1566–1572.
8 – Inoue et al. Ann Gastroenterol. 2015 Jan-Mar; 28(1): 41–48.
9 – Atkinson et al. Gastroenterology 2019 Aug;157(2):462-471.
10 – McGill et al. Gut. 2013 Dec;62(12):1704-13.
11 – Bisschops et al. Endoscopy 2019; 51: 1155–1179
12 – Dayyeh et al. Gastrointest Endosc. 2015 Mar;81(3):502.e1-502.e16.
13 – NICE DG28 published May 2017. Available online: https://www.nice.org.uk/guidance/dg28/